Drug Profile
Atherosclerosis vaccine - AFFiRiS
Alternative Names: ATH-03Latest Information Update: 13 Jul 2015
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Antihyperlipidaemics; Vaccines
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 12 Jul 2012 Affiris completes a phase I trial in Healthy volunteers in Austria (NCT01284582)
- 03 Nov 2011 Affiris completes enrolment in its phase I trial for Atherosclerosis in Austria (NCT01284582)
- 19 May 2011 Phase-I clinical trials in Atherosclerosis in Austria (Parenteral)